These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 11559308

  • 1. Early morning off-medication dyskinesias, dystonia, and choreic subtypes.
    Cubo E, Gracies JM, Benabou R, Olanow CW, Raman R, Leurgans S, Goetz CG.
    Arch Neurol; 2001 Sep; 58(9):1379-82. PubMed ID: 11559308
    [Abstract] [Full Text] [Related]

  • 2. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis.
    Olanow CW, Gracies JM, Goetz CG, Stoessl AJ, Freeman T, Kordower JH, Godbold J, Obeso JA.
    Mov Disord; 2009 Feb 15; 24(3):336-43. PubMed ID: 19006186
    [Abstract] [Full Text] [Related]

  • 3. [Levodopa-induced dyskinesia in 176 patients with Parkinson's disease].
    Rocha MS, Andrade LA, Ferraz HB, Borges V.
    Arq Neuropsiquiatr; 1995 Dec 15; 53(4):737-42. PubMed ID: 8729765
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Outcomes after stereotactically guided pallidotomy for advanced Parkinson's disease.
    Kondziolka D, Bonaroti E, Baser S, Brandt F, Kim YS, Lunsford LD.
    J Neurosurg; 1999 Feb 15; 90(2):197-202. PubMed ID: 9950488
    [Abstract] [Full Text] [Related]

  • 6. [Neurosurgical treatment for dopamine-induced dyskinesias in Parkinson's disease patients].
    Sugiyama K, Yokoyama T, Namba H.
    Nihon Rinsho; 2000 Oct 15; 58(10):2115-9. PubMed ID: 11068457
    [Abstract] [Full Text] [Related]

  • 7. Long-term pallidal deep brain stimulation in patients with advanced Parkinson disease: 1-year follow-up study.
    Loher TJ, Burgunder JM, Pohle T, Weber S, Sommerhalder R, Krauss JK.
    J Neurosurg; 2002 May 15; 96(5):844-53. PubMed ID: 12005391
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.
    Herring WJ, Assaid C, Budd K, Vargo R, Mazenko RS, Lines C, Ellenbogen A, Verhagen Metman L.
    Clin Neuropharmacol; 2017 May 15; 40(6):255-260. PubMed ID: 29059133
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F, Lilliu H, Le Pen C.
    Rev Neurol (Paris); 2001 May 15; 157(5):507-14. PubMed ID: 11438770
    [Abstract] [Full Text] [Related]

  • 15. Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease.
    Herz DM, Haagensen BN, Nielsen SH, Madsen KH, Løkkegaard A, Siebner HR.
    Mov Disord; 2016 Apr 15; 31(4):521-9. PubMed ID: 26954295
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The spectrum of levodopa-induced dyskinesias.
    Fahn S.
    Ann Neurol; 2000 Apr 15; 47(4 Suppl 1):S2-9; discussion S9-11. PubMed ID: 10762127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.